Erin M Hall1, Jeffrey Leonard2, Jodi L Smith3, Kristin P Guilliams4, Michael Binkley5, Robert J Fallon6, Monica L Hulbert1. 1. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Neurosurgery, The Ohio State University School of Medicine and Nationwide Children's Hospital, Columbus, Ohio. 3. Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Neurology, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Biostatistics, Washington University School of Medicine, St. Louis, Missouri. 6. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND: Children with sickle cell disease (SCD) and moyamoya may benefit from indirect cerebral revascularization surgery in addition to chronic blood transfusion therapy for infarct prevention. We sought to compare overt and silent infarct recurrence rates in children with SCD undergoing revascularization. METHODS: This was a retrospective cohort study of all children with SCD and moyamoya treated at two children's hospitals. Clinical events and imaging studies were reviewed. RESULTS: Twenty-seven children with SCD and confirmed moyamoya receiving chronic transfusion therapy were identified, of whom 12 underwent indirect cerebral revascularization. Two subjects had postoperative transient ischemic attacks and another had a subarachnoid blood collection, none of which caused permanent consequences. Two subjects had surgical wound infections. Among these 12 children, the rate of overt and silent infarct recurrence decreased from 13.4 infarcts/100 patient-years before revascularization to 0 infarcts/100 patient-years after revascularization (P = 0.0057); the postrevascularization infarct recurrence rate was also significantly lower than the overall infarct recurrence of 8.87 infarcts/100 patient-years in 15 children without cerebral revascularization (P = 0.025). CONCLUSIONS: The rate of overt and silent infarct recurrence was significantly lower following indirect cerebral revascularization. A prospective study of cerebral revascularization in children with SCD is needed.
BACKGROUND:Children with sickle cell disease (SCD) and moyamoya may benefit from indirect cerebral revascularization surgery in addition to chronic blood transfusion therapy for infarct prevention. We sought to compare overt and silent infarct recurrence rates in children with SCD undergoing revascularization. METHODS: This was a retrospective cohort study of all children with SCD and moyamoya treated at two children's hospitals. Clinical events and imaging studies were reviewed. RESULTS: Twenty-seven children with SCD and confirmed moyamoya receiving chronic transfusion therapy were identified, of whom 12 underwent indirect cerebral revascularization. Two subjects had postoperative transient ischemic attacks and another had a subarachnoid blood collection, none of which caused permanent consequences. Two subjects had surgical wound infections. Among these 12 children, the rate of overt and silent infarct recurrence decreased from 13.4 infarcts/100 patient-years before revascularization to 0 infarcts/100 patient-years after revascularization (P = 0.0057); the postrevascularization infarct recurrence rate was also significantly lower than the overall infarct recurrence of 8.87 infarcts/100 patient-years in 15 children without cerebral revascularization (P = 0.025). CONCLUSIONS: The rate of overt and silent infarct recurrence was significantly lower following indirect cerebral revascularization. A prospective study of cerebral revascularization in children with SCD is needed.
Authors: Christoph J Griessenauer; Jeffrey D Lebensburger; Michelle H Chua; Winfield S Fisher; Lee Hilliard; Christina J Bemrich-Stolz; Thomas H Howard; James M Johnston Journal: J Neurosurg Pediatr Date: 2015-04-03 Impact factor: 2.375
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Allison A King; John J Strouse; Mark J Rodeghier; Bruce E Compas; James F Casella; Robert C McKinstry; Michael J Noetzel; Charles T Quinn; Rebecca Ichord; Michael M Dowling; J Philip Miller; Michael R Debaun Journal: Am J Hematol Date: 2014-02 Impact factor: 10.047
Authors: Benjamin C Kennedy; Michael M McDowell; Peter H Yang; Caroline M Wilson; Sida Li; Todd C Hankinson; Neil A Feldstein; Richard C E Anderson Journal: Neurosurg Focus Date: 2014-01 Impact factor: 4.047
Authors: Todd C Hankinson; Leif-Erik Bohman; Geoffrey Heyer; Maureen Licursi; Saadi Ghatan; Neil A Feldstein; Richard C E Anderson Journal: J Neurosurg Pediatr Date: 2008-03 Impact factor: 2.375
Authors: M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad Journal: Blood Adv Date: 2020-04-28